Blockchain

Prophecy DeFi Inc. (CSE: PDFI) ("Prophecy DeFi", "Prophecy", or the "Company"), a publicly traded investment firm focused on the decentralized finance (DeFi) sector, is pleased to announce the appointment of Paul Rekai as President & Head of Operations.

Paul will lead the next chapter of Prophecy's operations and growth. In this position, Paul will complement Prophecy's existing leadership team of experienced traditional finance and crypto operators and look to expand revenue streams by providing essential financial services for DeFi projects and investors alike.

Paul is a crypto-native investor and operator, with experience working directly with on-chain DeFi Projects and investor-facing roles, bringing traditional investors into the world of crypto. Most recently, Paul was head of Business Development at AltFi Capital, a Digital Asset Hedge Fund and Investor Service Provider. In addition, Paul has served as a key advisor to SX Network, the largest blockchain-based betting site in the world. Paul has deep expertise in DeFi, through operational experience with Decentralized Exchanges (DEXs) and Automated Market Makers (AMMs) in yield farming and liquidity provision activities.

"We are extremely excited to have Paul join Prophecy's leadership team as we focus on driving more operational growth," said John McMahon, CEO, Prophecy DeFi. "Paul has the skills and experience necessary to help grow the business in a meaningful way."

In connection with Mr. Rekai's appointment the Company has granted him an aggregate of 3,000,000 options to purchase common shares of the Company, with 1,000,000 options each exercisable at prices of $0.05, $0.10 and $0.15, vesting over a 2 year period and expiring three (3) years from the date of issuance. The common shares issuable upon exercise of the options are subject to a four month hold period from the original date of grant.

About Prophecy DeFi

Prophecy DeFi (CSE: PDFI) provides retail and institutional investors with access to the decentralized finance sector by bridging the gap between DeFi and traditional finance. Prophecy DeFi invests in diverse DeFi and Web 3.0 startups to create new business opportunities in a coherent ecosystem.

www.prophecydefi.com

For further information, please contact:

John McMahon, CEO
Tel: (416) 764-0314
Email: jmcmahon@prophecydefi.com

Forward-Looking Information

Certain information set forth in this news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals and the possibility that the completion of the transaction may not occur. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/142191

News Provided by Newsfile via QuoteMedia

PDFI:CC
Prophecy Defi

Prophecy DeFi


Keep reading...Show less
Prophecy DeFi Announces Resignation of Director

Prophecy DeFi Announces Resignation of Director

Prophecy DeFi Inc. (CSE: PDFI) ("Prophecy DeFi" or the "Company"), announces the resignation of Stuart Hensman from the Board of Directors (the "Board").

"On behalf of the Company, I would like to thank Stuart for his contributions to the Board. We wish him all the best in his future endeavours," said John McMahon, CEO, Prophecy DeFi.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Prophecy DeFi Announces Q1 2022 Financial Results

Prophecy DeFi Announces Q1 2022 Financial Results

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Prophecy DeFi Inc. (" Prophecy DeFi " or the " Company ") (CSE: PDFI), a publicly traded investment firm focused on the decentralized finance sector, is pleased to announce its financial results for the three months ended March 31, 2022 ("Q1").

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
PROPHECY DEFI'S INVESTMENT COMPANY LAYER2 BLOCKCHAIN CONTINUES TO IDENTIFY AND DEPLOY CAPITAL INTO HIGH YIELD DEFI OPPORTUNITIES

PROPHECY DEFI'S INVESTMENT COMPANY LAYER2 BLOCKCHAIN CONTINUES TO IDENTIFY AND DEPLOY CAPITAL INTO HIGH YIELD DEFI OPPORTUNITIES

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
FOR DISSEMINATION IN THE UNITED STATES /

Prophecy DeFi Inc. (" Prophecy DeFi ", " Prophecy " or the " Company ") (CSE: PDFI) is pleased to provide investors with an operational update on its wholly owned subsidiary, Layer2 Blockchain Inc. (" Layer2 Blockchain ", " Layer2 ", or the " Company ").

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
PROPHECY DEFI ANNOUNCES GRANT OF OPTIONS

PROPHECY DEFI ANNOUNCES GRANT OF OPTIONS

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
FOR DISSEMINATION IN THE UNITED STATES /

 Prophecy DeFi Inc. (" Prophecy DeFi " or the " Company ") (CSE: PDFI) announces that it has granted an aggregate of 1,400,000 options to purchase common shares of the Company to an officer and consultants of the Company, exercisable at a price of $0.60 per common share for a period of three (3) years from the date of grant, in accordance with the terms of the Company's stock option plan. The common shares issuable upon exercise of the options are subject to a statutory hold period of four months and one day from the date of grant.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
debenture fund

Prophecy DeFi Announces Closing of Brokered Private Placement of Convertible Debenture Units

Prophecy DeFi Inc. (CSE: PDFI) ("Prophecy DeFi" or the "Company") is pleased to announce that it has closed its previously announced brokered private placement of an aggregate of 5,680 convertible debenture units of the Company (the "Debenture Units") at an issue price of $1,000 per Debenture Unit for aggregate gross proceeds of $5,680,000 (the "Offering").

Each Debenture Unit is comprised of $1,000 principal amount of 10.0% unsecured convertible debentures of the Company (the "Convertible Debentures") and 1,667 common share purchase warrants of the Company (the "Warrants"). Each Convertible Debenture matures 36 months following the closing of the Offering (the "Maturity Date") and bears interest at a rate of 10.0% per annum from the date of issue, payable quarterly in cash. The Convertible Debentures are convertible into common shares of the Company ("Common Shares") at the option of the holder at any time prior to the Maturity Date, or on the business day immediately preceding a date fixed for redemption of the Convertible Debentures, at a conversion price equal to $0.60 per Common Share (the "Conversion Price"). Upon conversion, the holder will receive accrued and unpaid interest on the principal amount of the Convertible Debentures that is the subject of the conversion for the period from and including the date of the latest interest payment date to, but excluding, the date of conversion. The Conversion Price is subject to adjustment upon the occurrence of certain customary events. The Company has the right to force conversion of the Convertible Debentures at the Conversion Price if the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the "CSE") is greater than $1.20 for 10 consecutive trading days. Upon a change of control of the Company, holders of Convertible Debentures have the right to require the Company to repurchase their Convertible Debentures, in whole or in part, on the date that is 30 days following notice of the change of control at a price equal to 105% of the principal amount of the Convertible Debentures then outstanding plus accrued and unpaid interest thereon.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Graphene Manufacturing Group Announces Closing of $5.7M Bought Deal Offering

Graphene Manufacturing Group Announces Closing of $5.7M Bought Deal Offering

Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that the Company closed its previously announced bought deal prospectus offering of units (the "Units") of the Company, including exercise in full of the over-allotment option (the "Offering"). A total of 2,091,850 Units were sold at a price of C$2.75 per Unit (the "Offering Price") for gross proceeds of approximately C$5.75 million.

Each Unit is comprised of one ordinary share in the capital of the Company (each, an "Ordinary Share") and one Ordinary Share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one Ordinary Share at a price of C$3.35, at any time until November 30, 2026. The Offering was completed pursuant to an underwriting agreement dated November 14, 2022 among the Company and Eight Capital, as lead underwriter and sole bookrunner, and a syndicate of underwriters including Raymond James Ltd., H.C. Wainwright & Co., LLC, Leede Jones Gable Inc., PI Financial Corp., and Research Capital Corporation (collectively, the "Underwriters").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005423/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Greenlane Renewables Announces Dairy RNG System Sales Contract

Greenlane Renewables Announces Dairy RNG System Sales Contract

~Greenlane to supply a biogas upgrading system for a new project in the Western U.S.~

 Greenlane Renewables Inc. (" Greenlane ") (TSX: GRN) (FSE: 52G) is pleased to announce that its wholly-owned subsidiary, Greenlane Biogas North America Ltd., has been awarded a $4.6 million ( US$3.5 million ) contract for a dairy RNG project in the Western United States for the supply of a biogas upgrading system. Greenlane will supply its pressure swing adsorption system for upgrading biogas generated from anaerobic digestion of dairy cow manure into carbon negative renewable natural gas ("RNG") suitable for injection into the local pipeline network. Order fulfillment is expected to commence immediately.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Reports Third Quarter Results for 2022 and Company Update

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2022. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin states, "As we continue to focus our efforts and resources on PlanteinTM Plant-Based Foods and our ten (10) year exclusive manufacturing and distribution agreement with Flexitarian Foods PTY Ltd., there have been many positives as well as a number of challenges. The positives include our recent launch into retail, and the return to trade shows where are products have been getting exceptional reviews, as well as our expanding relations with our national distributors. However, the Company has experienced significant challenges as well, the most notable being the continued delay of customized manufacturing lines being assembled in Shanghai, China. The delay to date has been due to a combination of shortage of computer chips, combined with on-going Covid challenges and subsequent quarantining in Shanghai".

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Nanalysis Reports Third Quarter 2022 Results

Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for healthcare and industrial applications, releases its second quarter results ending September 30, 2022. Chief Executive Officer, Sean Krakiwsky and Interim Chief Financial Officer, Randall McRae will host a conference call at 5 P.M. Eastern Time today to discuss the results. A second call will be held for European investors at 8:30am ET on Wednesday, November 30 th . All interested parties are invited to join these calls.

Nanalysis Scientific Corp. (CNW Group/Nanalysis Scientific Corp.)

"I am pleased to report we have returned to our strong growth trajectory in the third quarter," said Sean Krakiwsky, Founder and CEO of Nanalysis. "We continue to focus on growing all segments of our organization and executing on our operational strategy. In the third quarter we laid significant groundwork on our previously announced multi-year airport security contract with the Canadian Air Transportation Security Authority and have now begun operations on that project in the fourth quarter. We believe we have also resolved the issues that slowed our growth in our benchtop NMR sales organization in the second quarter, returning to strong benchtop NMR sales figures. We expect to see continued strength in our business in the fourth quarter, which has historically been a strong quarter for our business."

Financial highlights (unaudited) for the three months ended September 30, 2022:

  • For the three months ended September 30, 2022 , the Company reported consolidated revenue of $6,878K , an increase of $3,542K or 106% from the comparative period in 2021. This includes $6,145K in product sales and $733K of service revenue related to airport security services.
  • Gross margin on total sales was 43% for the three months ended September 30, 2022 . This was the result of increased training costs of personnel for the CATSA airport security project, increased personnel and training in Nanalysis' manufacturing group to increase manufacturing capacity, an increase in costs due to worldwide supply chain constraints and inflation, as well as a specific medical imaging project in our RS2D subsidiary that had lower than normal gross margins. Management expects margins to improve as continued investments in manufacturing improvements continue, sales levels increase, and the CATSA airport security project continues to phase-in to full capacity.
  • (Loss) Income before other items for the three months ended September 30, 2022, was $( 618K ) versus $12K compared to the same period last year.
  • Net loss for the three months ended was $(2,599K), as compared to the three-month loss for September 30, 2021, of $(857K).
  • The Company had cash on hand of $7,925K, an undrawn credit facility of $6,734K, working capital of $9,658K and an undrawn government contribution funding of $4,985K as of September 30, 2022.

Recent strategic and operational highlights during and subsequent to the second quarter of 2022 include:

  • Funding received from Prairies Economic Development Canada: Subsequent to September 30, 2022 , the Company received its first $1.5 million in funding from the Business Scale-up Program. This program will provide Nanalysis up to $4,985K of funding in the form of an unsecured interest free loan. The program is designed to help fast growing tech firms scale-up and enter new markets.
  • Consolidation of credit facility: On November 18, 2022 , the Company closed a credit line with a major Canadian bank, consolidating its existing operating facilities into a $9 million operating line.  The line bears interest at a rate of prime plus 0.65% and will allow the Company to execute on its growth and expansion plans.
  • Security Service : In November 2022 , the Company began providing services under the CATSA airport security contract and continues to execute successfully on its phase-in plan for the entire project.
  • Manufacturing : In addition to Nanalysis investing in a state of the art five axis machining centre and wire electrical discharge machine in the second quarter of 2022, Nanalysis has also invested in growing out the manufacturing team allowing the Company to meet expected growth in demand as it heads into 2023.
  • Quad Systems : The company has seen continued development with Quad System's full high-field NMR product. Module sales have continued to increase in the third quarter and the Company expects material revenue from the acquisition in 2023.
Operating Results

For the nine months ended September 30, 2022 , the Company reported consolidated revenue of $17,618K , an increase of $6,664K or 61% from the comparative period in 2021. The increase from Q3 2021 can be attributed to continued increases in shipments of the 100MHz benchtop NMR unit, coupled with revenue from the recent acquisition, K'Prime, offset by lower RS2D revenue than in Q3 2021.

Gross profit for the nine months ended September 30, 2022 , was $9,504K (a margin of 54%) compared to gross profit of $7,152K (a margin of 65%) for the nine months ended September 30, 2021 . Margins for the nine months ended September 30, 2022 , decreased over the nine months ended September 30, 2021 , as a result of increased component costs because of world-wide supply chain challenges, low margins on a specific Q3 project in RS2D, training costs included in cost of services related to the CATSA airport security project phase in, and investments made in the Company's manufacturing workforce beginning in the second quarter.

The Company's net loss for the nine months ended was $(6,623K) , as compared to the nine-month loss for the period ended September 30, 2021 , of $(1,127K) . The increased loss was due to higher sales and marketing expenses, increased general and administration expenses and increased research and development expenses, both in the Nanalysis segment and from the new acquisitions. In addition, there were business acquisition costs from the two transactions completed, increased depreciation and amortization expense, and increased finance expenses partially offset by no RS2D earnout in the quarter and increased revenues.

Outlook

"Our main objective continues to be focusing on executing our business plan, including ramping up sales of our 100 MHz product, completing the roll out of the CATSA airport service contract, and capitalizing on business opportunities brought by our recent acquisitions. We have successfully restructured and refocused our benchtop NMR salesforce and expect growing demand in 2023 for benchtop products, and we continue to work towards the launch of a full multi-module high-field NMR product via Quad Systems," said Sean Krakiwsky .

"With a slower second quarter well behind us, we have returned to our high growth trajectory and continue to have confidence that Nanalysis is well positioned for solid growth in 2023 and the years to come. Operational excellence remains our mantra, as we will continue to leverage existing customer relationships, our innovative technologies, and a motivated and professional team to fuel growth. We are confident that we will deliver the value we've created by our recent acquisitions to our shareholders through the remainder of 2022 and into the new year," concluded Mr. Krakiwsky.

Conference Call

Investors interested in participating on the live call can dial 1-888-664-6392 or 416-764-8659 from abroad. Investors can also access the call online through a listen-only webcast here:
https://app.webinar.net/JoLVkw4jEmX or on the investor relations section of the Company's website HERE . The webcast will be archived on the Company's investor relations webpage for at least 90 days and a telephonic playback will be available for seven days after the conference call by calling 1-888-390-0541 or 416-764-8677, conference ID # 833132.

Additionally, the Company will be hosting a Q&A session for it's European investors tomorrow, Wednesday, November 30 th at 8:30am ET which can be accessed by the following link: : Click here to join the meeting , or call in (audio only) +1 437-703-4522, Phone Conference ID: 295 204 525#.

About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA:1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The Company has followed up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis began selling a 100MHz device in 2020. The Company's new device is the most powerful and most advanced compact NMR device ever brought to market.  Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'Prime, the Company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems and services for security applications.  Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares.  Quad Systems is a Zurich-based Nuclear Magnetic Resonance ("NMR") company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/nanalysis-reports-third-quarter-2022-results-301689459.html

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2022/29/c7594.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Avricore Health Reports Third-Quarter 2022 Results

Avricore Health Reports Third-Quarter 2022 Results

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") today released its Q3 results which demonstrate significant revenue growth, indicating it can scale sustainably and deliver on its long-term objectives.

The Company's objective to create the world's first cloud-connected point-of-care network in community pharmacy is on track to becoming a reality, bringing powerful health screening and data management tools to community pharmacies and ensuring better outcomes for patients.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×